Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative therapy in type 2 diabetes mellitus (T2DM), offering benefits that extend beyond glycemic control. The gene discussed is SLC5A2; the disease is diabetes mellitus.